Published in Am J Surg Pathol on January 01, 2010
Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol (2011) 1.37
HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res (2011) 1.27
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci (2013) 1.14
Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol (2012) 1.13
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol (2013) 0.95
Ovarian cancer: opportunity for targeted therapy. J Oncol (2011) 0.90
miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res (2013) 0.87
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Arch (2012) 0.86
Three-gene molecular diagnostic model for thyroid cancer. Thyroid (2012) 0.85
FSH stimulates expression of the embryonic gene HMGA2 by downregulating let-7 in normal fimbrial epithelial cells of ovarian high-grade serous carcinomas. Exp Ther Med (2012) 0.78
Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol (2014) 0.78
Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis. Am J Cancer Res (2016) 0.77
Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget (2015) 0.76
MicroRNA-495 Inhibits Gastric Cancer Cell Migration and Invasion Possibly via Targeting High Mobility Group AT-Hook 2 (HMGA2). Med Sci Monit (2017) 0.75
[Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis]. Pathologe (2011) 0.75
The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer. Biomed Rep (2017) 0.75
MicroRNA-495 Inhibits New Bone Regeneration via Targeting High Mobility Group AT-Hook 2 (HMGA2). Med Sci Monit (2017) 0.75
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell (2002) 6.05
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 2.81
Structural basis of transcription activation: the CAP-alpha CTD-DNA complex. Science (2002) 2.67
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
Signet-ring cell change versus signet-ring cell carcinoma: a comparative analysis. Am J Surg Pathol (2003) 2.51
A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer (2007) 2.35
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Cellular senescence in usual type uterine leiomyoma. Fertil Steril (2009) 2.34
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med (2005) 2.30
Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res (2004) 2.24
Adoptive transfer with in vitro expanded human regulatory T cells protects against porcine islet xenograft rejection via interleukin-10 in humanized mice. Diabetes (2012) 2.17
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol (2003) 1.99
CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell (2008) 1.94
Diversity of 16S rRNA genes within individual prokaryotic genomes. Appl Environ Microbiol (2010) 1.93
Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res (2007) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol (2007) 1.77
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther (2009) 1.69
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem (2005) 1.64
Tissue macroarray: a simple and cost-effective method for high-throughput studies. Appl Immunohistochem Mol Morphol (2003) 1.61
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61
Glypican 3 has a higher sensitivity than alpha-fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns. Histopathology (2010) 1.61
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle (2009) 1.60
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol (2005) 1.56
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer (2006) 1.55
Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol (2009) 1.53
Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res (2008) 1.53
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res (2008) 1.52
Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem (2008) 1.52
Mifepristone inhibits GRβ coupled prostate cancer cell proliferation. J Urol (2012) 1.51
Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res (2005) 1.51
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer (2007) 1.48
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res (2014) 1.46
Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis. Anticancer Drugs (2013) 1.42
Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res (2004) 1.41
MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol (2012) 1.38
Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem (2005) 1.38
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci U S A (2006) 1.37
Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci U S A (2004) 1.34
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res (2009) 1.34
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol (2014) 1.33
Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure (2006) 1.32
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer (2006) 1.32
Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res (2010) 1.31
CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol (2011) 1.30
Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol (2007) 1.29
Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status. Hum Pathol (2003) 1.29
HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res (2011) 1.27
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem (2003) 1.27
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer (2006) 1.25
Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene (2003) 1.24
Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2008) 1.23
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer (2009) 1.23
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst (2005) 1.23
Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression. PLoS One (2013) 1.23
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res (2004) 1.22
Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol (2004) 1.22
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res (2003) 1.22
CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol (2008) 1.21
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res (2005) 1.20
The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol (2005) 1.19
The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res (2011) 1.19
Comprehensive assessment of heavy metal contamination in sediment of the Pearl River Estuary and adjacent shelf. Mar Pollut Bull (2012) 1.19
Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure (2013) 1.18
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res (2009) 1.17
Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem (2004) 1.17
Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle (2012) 1.16
Molecular genetics of hepatocellular neoplasia. Am J Transl Res (2010) 1.16
Paris saponin II of Rhizoma Paridis--a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends (2012) 1.15
Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol (2010) 1.15
The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res (2008) 1.14